Curium has an unbroken
commitment to redefining the
cancer experience
From our legacy in nuclear imaging to our future vision of theranostics, we never leave the picture.
At Curium, our commitment to the
fight against cancer is unbreakable.
From diagnosis to treatment, our sole focus is delivering effective, targeted, and seamless solutions that enhance the lives of patients living with cancer.
Reinforcing our promise
to theranostics
With more than 100+ years' experience, Curium is leveraging its expertise to help transform the treatment landscape with a robust precision theranostics pipeline.
Swipe for more
FOUNDATIONS IN
IMAGING
Began production of x-ray agents, laying the groundwork for future diagnostic innovation
PIONEERING NUCLEAR MEDICINE
Launched our first SPECT imaging product, opening the door to a new class of diagnostic tools
SPECT, single photon emission computed tomography.
PIONEERING NUCLEAR MEDICINE
Gained FDA approval for the first ever peptide-based radiopharmaceutical1 and expanded into multiple indications with agents for oncology, cardiology, and pulmonary imaging
PIONEERING NUCLEAR MEDICINE
Advanced into therapeutic applications with iodine-based agents and bone-targeted radiopharmaceuticals
DRIVING THE PET REVOLUTION
Introduced our first positron emission tomography (PET) imaging agent in Europe, establishing PET as a cornerstone of modern oncology
DRIVING THE PET REVOLUTION
Expanded the European PET portfolio with next-generation tracers across neurology, cardiology, and prostate cancer
DRIVING THE PET REVOLUTION
Advanced SSTR PET imaging with the launch of a copper-based agent in the US, reinforcing leadership in precision diagnostics
SHAPING THE FUTURE WITH THERANOSTICS
Clinical trials to expand radioligand therapy and next-generation imaging for NETs and prostate cancer begin, signaling a new era of integrated diagnosis and treatment.
Supporting cancer patients—now and always
Curium’s purpose is firmly built around patients, caregivers, and healthcare professionals. For more than 30 years, we’ve supported the neuroendocrine tumor (NET) community, not only with the first somatostatin receptor (SSTR) imaging for NETs, but also through advocacy and education.
As we bring our expertise to therapeutics, our purpose remains the same—to advance solutions through deep commitment, meaningful partnerships, and relentless focus on improving outcomes.
Resources for patients with NETs or prostate cancer
Support patients' understanding of nuclear medicine with these video resources.
Removing barriers for a seamless experience
Operational
excellence
Delivering nuclear medicines for oncology requires more than scientific expertise–it demands a deep understanding of the real-world barriers that providers and institutions face every day.
Tackling
challenges
Curium is tackling the logistical, operational, financial, and educational challenges that stand in the way of timely care.
Focused
approach
Backed by our vertically integrated manufacturing and distribution network, our focused approach helps simplify delivery and expand access to life-changing radiopharmaceuticals.
Discover how our integrated manufacturing network drives reliability
Join us in shaping the future of theranostics in oncology
Register to receive updates on radioligand therapy, new approvals, upcoming events, and clinical resources.
Reference
Levine R, Krenning EP. Clinical history of theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: historical review based on an interview of Eric P. Krenning by Racheal Levine. J Nucl Med. 2017;58:3S-9S. doi:10.2967/jnumed.116.186502